6610.TWO TWi Biotechnology, Inc.
- Market cap
- TWD 4.05B
- P/E
- -
- P/B
- 8.48x
- ROE
- -56.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6610.TWO undervalued?
Graham numberThe Graham number of TWi Biotechnology, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TWi Biotechnology, Inc. fundamental analysis
No fundamental analysis for TWi Biotechnology, Inc. yet.
TWi Biotechnology, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic derma…
Full company profileTWi Biotechnology, Inc. financial statements
TWi Biotechnology, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 9.66M | 1.25M | 66.4M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.36M | 203K | 65.5M | -10.4M | -9.74M | -9.70M | 0.00 |
| Operating Income | -114M | -98.6M | -15.3M | -90.2M | -170M | -178M | -357M |
| EBITDA | -103M | -88.8M | -4.11M | -65.8M | -161M | -155M | -322M |
| Net Income | -112M | -102M | -15.3M | -76.2M | -171M | -165M | -358M |
| EPS | -1.59 | -1.45 | -0.22 | -1.13 | -2.20 | -1.77 | -1.76 |
| Balance Sheet | |||||||
| Total Assets | 429M | 387M | 311M | 234M | 397M | 242M | 724M |
| Total Liabilities | 5.19M | 92.9M | 32.2M | 28.4M | 55.8M | 66.5M | 93.1M |
| Shareholders' Equity | 396M | 294M | 279M | 206M | 341M | 176M | 630M |
| Cash & Short-term Investments | 329M | 212M | 223M | 160M | 324M | 176M | 264M |
| Total Debt | - | 7.49M | 5.02M | 2.53M | 7.97M | 15.6M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -97.8M | -62.6M | -34.5M | -60.2M | -134M | -155M | -287M |
| Capital Expenditure | 243K | 30.0M | 30.2M | 0.00 | 134M | 308K | 5.86M |
| Free Cash Flow | -98.1M | -92.6M | -64.7M | -60.2M | -134M | -156M | -293M |
| Ratios | |||||||
| ROE | -28.2% | -34.6% | -5.5% | -37.0% | -50.0% | -93.7% | -56.7% |
| ROA | -26.0% | -26.3% | -4.9% | -32.5% | -43.0% | -68.0% | -49.4% |
| Net Profit Margin | -1,154.0% | -8,174.8% | -23.0% | - | - | - | - |
| Debt to Equity | - | 0.03x | 0.02x | 0.01x | 0.02x | 0.09x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TWi Biotechnology, Inc. dividends
TWi Biotechnology, Inc. has not paid dividends in the last 7 fiscal years.
Who owns TWi Biotechnology, Inc.
Ownership data of TWi Biotechnology, Inc. is not available yet.
TWi Biotechnology, Inc. company profile
- Company name
- TWi Biotechnology, Inc.
- Ticker
- 6610.TWO
- ISIN
- TW0006610009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- No. 41, Lane 221, Taipei, Taiwan, 114723
- Phone
- 886 2 2657 1788
- Website
- twibiotech.com
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases; and NORA520, an oral prodrug, which is hydrolyzed to Brexanolone. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan. TWi Biotechnology, Inc. operates as a subsidiary of Xinchen Investment Company.
TWi Biotechnology, Inc. management
5- Dr. Chen-En Tsai M.D., Ph.D.President, Director & Chief Medical Officer
- Dr. Chih-Ming Chen Ph.D.Founder
- Li Juan HuangAccounting Supervisor
- Mr. Guang-Wei Lu Ph.D.Senior Vice President of R&D
- Dr. Michelle Chen Ph.D.Head of Business Development